Scope Fluidics, a life sciences company listed on the Warsaw Stock Exchange and focused on developing innovative technologies for medical diagnostics and healthcare, ended 2024 with over PLN 150 million in cash. The Group reported net profit of PLN 65.4 million for the year.
The key event of 2024 was the Group’s agreement with Bio-Rad Laboratories, under which Scope Fluidics received USD 30 million as the final settlement related to the sale of its special-purpose vehicle (SPV), Curiosity Diagnostics. Following completion of the agreement, the total transaction value reached USD 130 million — the largest deal in the history of Poland’s life sciences sector.
The Group is currently developing three special-purpose vehicles: BACTEROMIC, which is entering the European market this year, and two early-stage companies emerging from Scope Discovery — EDOCERA and HYBOLIC.
“2024 was a year of systematic, intensive work on executing our strategy, and one of important achievements. We finalized the historic sale of Curiosity Diagnostics to Bio-Rad with an additional USD 30 million payment. We have proven our ability to negotiate and close major transactions, and we value our constructive relationship with such a highly regarded partner as Bio-Rad Laboratories. The success of PCR|ONE and Scope Fluidics has strengthened our position in the international market and inspires us to pursue further ambitious goals. In 2024, we focused the majority of our attention, effort, and capital on developing BACTEROMIC, which is emerging as a unique solution combining speed, throughput, and multitasking capabilities in automated antibiotic susceptibility testing. BACTEROMIC responds effectively to the demands of a growing and evolving AST market. The results of the Early Access Program confirmed the system’s readiness for commercialization — we are currently undergoing IVDR certification and preparing for FDA approval in the United States. We are also investing in a semi-automated production line for BACTEROMIC panels, in collaboration with a NYSE-listed global leader in industrial technologies,” said Piotr Garstecki, President of Scope Fluidics.
In 2024, Scope Discovery — the Group’s internal venture studio responsible for creating and developing new projects within a structured, repeatable model — recorded significant growth. By year-end, 48 projects had been submitted for evaluation through the Scope Discovery process; 16 were completed and 30 have remained in progress.
Scope Fluidics is currently advancing two additional innovation projects as subsidiaries originating from Scope Discovery:
The Group ultimately aims to develop several special-purpose vehicles (SPVs) in parallel, each supported by a dedicated and fully committed team and management structure. Notably, in early 2025, Scope Fluidics achieved — ahead of schedule — the first strategic objective from its Development Strategy published in 2023. The strategy had set a target of adding at least five new projects to the portfolio by the end of 2025, including at least two operated as SPVs.
Strong Cash Position for Challenging Times
As of December 31, 2024, the Group held over PLN 150 million in cash (approximately PLN 129 million in cash and bank accounts, and around PLN 22 million in investment fund units), and reported net profit of PLN 65.4 million for the year.
“We recorded a strong net profit following the finalization of the Curiosity Diagnostics sale. This transaction has significantly bolstered the financial resources necessary for continued project development. Currently, we are investing the majority of our funds in BACTEROMIC, preparing it for a potential transaction. It is important to emphasize that investing in advanced technologies is a long-term process that requires not only specialized expertise and a strong knowledge base, but also prudent and flexible financial management. This has been our approach for many years,” said Szymon Ruta, Vice President and Financial Director of Scope Fluidics.
Post-Reporting Period Event: No Dividend Recommended
The Management Board of Scope Fluidics has recommended not paying a dividend from 2024 profit.
This decision was made in response to the current international, geopolitical, and market conditions. In the Board’s view, it is not possible at this time to predict either the extent or duration of potential negative impacts stemming from the current environment. The sale of the BACTEROMIC system remains a strategic priority in building shareholder value. The Board believes that preserving financial flexibility will strengthen the Group’s negotiating position in preparing for a potential M&A transaction.
“This was one of the more difficult decisions we have faced. Nonetheless, I am convinced it is the right one. When preparing our recommendation for the General Shareholders’ Meeting, our priority was to protect initiatives that build long-term value. We are proud of the progress made across our projects and within Scope Discovery, and we continue to scale our operations. We are building on the know-how and talent of our teams to replicate the success of PCR|ONE — which delivered a return many times greater than the invested capital and enabled a dividend payout of PLN 233.3 million in 2023,” said Piotr Garstecki, President of Scope Fluidics.
